Journal Article

DZNE-2025-01348

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease.

Abdelmoity, O. ; Wisch, J. K. ; Kennedy, J. T. ; Goyal, M. ; Vlassenko, A. ; Flores, S. ; Handen, B. L. ; Head, E. ; Keator, D. ; Rafii, M. S. ; Lao, P. ; Lai, F. ; Rosas, H. D. ; Hartley, S. L. ; Zaman, S. ; Brickman, A. M. ; Tudorascu, D. ; Lee, J. H. ; Allegri, R. F. ; Keefe, S. ; la Fougère, C.DZNE* ; Llibre-Guerra, J. ; Ikeuchi, T. ; Morris, J. C. ; Roh, J. H. ; Day, G. S. ; Levin, J.DZNE* ; Schofield, P. R. ; Gordon, B. A. ; Benzinger, T. L. S. ; Ances, B. M. ; Syndrome, A. B. C. ; Network, t. D. I. A. (Collaboration Author)

2025
Wiley-Blackwell Hoboken, NJ

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/ana.78002

Abstract: Directly compare the brain glucose patterns seen with [F-18] fluorodeoxyglucose (FDG) positron emission tomography (PET) between 2 genetically determined forms of Alzheimer's disease: Down syndrome (DS) and autosomal dominant Alzheimer's disease (ADAD).Cross-sectional analyses of FDG were performed in individuals with DS (n = 76) from the Alzheimer Biomarker Consortium-Down Syndrome (ABC-DS), ADAD (n = 297), and neurotypical familial controls (n = 188) from the Dominantly Inherited Alzheimer Network (DIAN). Within-group linear regression models and generalized additive models were performed for select regional FDG uptake measures (isthmus cingulate and inferior parietal, precuneus, middle temporal gyrus, and precentral gyrus). Age, sex, apolipoprotein (APOE) ε4 carrier status, and cortical amyloid burden were included within these analyses.Even 20 years before expected onset of clinical symptoms, FDG uptake was lower for DS compared to neurotypical familial controls (p < 0.01). ADAD baseline FDG was similar to neurotypical familial controls until 7 years before expected symptom onset. Both symptomatic individuals with DS and ADAD had lower FDG compared to neurotypical familial controls (p < 0.01). A higher amyloid burden was associated with lower FDG for both genetic forms, with similar rates of decline in FDG uptake for DS and ADAD who were amyloid positive.Brain glucose metabolism is substantially lower for people with DS, even in individuals who are cognitively stable. The patterns of FDG decline are distinct in these 2 genetically determined forms of AD. The diagnostic utility of FDG-PET is specific to the genetic form of AD. ANN NEUROL 2025;98:1237-1248.

Keyword(s): Humans (MeSH) ; Alzheimer Disease: diagnostic imaging (MeSH) ; Alzheimer Disease: genetics (MeSH) ; Alzheimer Disease: metabolism (MeSH) ; Male (MeSH) ; Female (MeSH) ; Fluorodeoxyglucose F18: metabolism (MeSH) ; Cross-Sectional Studies (MeSH) ; Down Syndrome: diagnostic imaging (MeSH) ; Down Syndrome: metabolism (MeSH) ; Down Syndrome: genetics (MeSH) ; Positron-Emission Tomography (MeSH) ; Middle Aged (MeSH) ; Adult (MeSH) ; Aged (MeSH) ; Brain: diagnostic imaging (MeSH) ; Brain: metabolism (MeSH) ; Radiopharmaceuticals (MeSH) ; Glucose: metabolism (MeSH) ; Fluorodeoxyglucose F18 ; Radiopharmaceuticals ; Glucose

---

Contributing Institute(s):

1. Clinical Neurodegeneration (AG Levin)
2. Clinical Research (Munich) (Clinical Research (Munich))
3. Tübingen common (Tübingen common)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
2. 899 - ohne Topic (POF4-899) (POF4-899)

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Wiley ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 10 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---